BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical…
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via IBN — Lucy Scientific Discovery (NASDAQ: LSDI) today announces its placement…
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…
SILVER SPRING, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products,…
Dosing is progressing on schedule in ongoing ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in…
Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6…
The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated…
ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs…
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platformThe collaboration will access mRNA technology from the…
Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP) And Internal Debt Restructuring First regulatory agency…